The Zydus Group unit, Cadila Healthcare Ltd, has signed a contract to acquire the assets of Nesher Pharmaceuticals Inc. The procurement consists of Abbreviated New Drug Application pipeline, some manufacturing amenities and a research and development laboratory. This acquiring includes some liabilities as well.

Nesher is an US-based pharmaceutical company which deals in niche therapies used in managing the obstacles of production and growth by DEA-controlled substances and controlled release medications.

Now Zydus will be able to produce and sell generic controlled substances that previously could not be traded in. The overall cost of the controlled substances medications in U. S is around $7 billion. The niche unit prevails with $ 2.1 billion share in the U. S market. This purchase will help in the future growth of the Cadila.

Pankaj Patel, Chairman, Cadila Healthcare, said, "difficult-to-develop product pipeline, expertise and infrastructure that will add value to our operations in the U. S". He stated that the acquiring will reinforce the generic operations with the technological advancement of generics.

Zydus Cadila has not revealed any economic details of the agreement. But, according to the agreement the contract will shut after Cadila deposits $7.5 million, which will probably close around the second quarter of financial year 2012.